Table IV.
Formulation | Visual observation | % ATRA content | |||||
---|---|---|---|---|---|---|---|
Autoclave | Kept at 4°C for (days) | ||||||
ATRA crystallization | Phase separation | 14 | 28 | 42 | 56 | ||
S/CP-ATRA 1 mg/g | – | No | 69.07 | 98.86 | 95.97 | 93.56 | 92.48 |
S/CP-ATRA 3 mg/g | – | No | 70.24 | 98.76 | 96.18 | 92.55 | 91.27 |
M/CP-ATRA 1 mg/g | – | No | 70.74 | 99.23 | 96.16 | 94.08 | 92.03 |
M/CP-ATRA 3 mg/g | – | No | 70.41 | 99.08 | 96.58 | 94.56 | 92.79 |
M/CP-ATRA 5 mg/g | – | No | 69.45 | 98.89 | 95.03 | 93.17 | 92.01 |
S/O/CP-ATRA 1 mg/g | – | No | 71.50 | 98.55 | 96.19 | 94.99 | 93.45 |
S/O/CP-ATRA 3 mg/g | – | No | 70.01 | 99.08 | 97.51 | 95.69 | 92.96 |
S/O/CP-ATRA 5 mg/g | – | No | 72.16 | 98.89 | 97.23 | 95.93 | 93.96 |
S/O/CP-ATRA 7 mg/g | + | No | 71.19 | 98.90 | 97.12 | 95.43 | 92.43 |
S/O/CP-ATRA 9 mg/g | + | No | 68.86 | 98.53 | 96.10 | 95.10 | 92.33 |
M/O/CP-ATRA 1 mg/g | – | No | 73.77 | 98.97 | 97.04 | 95.04 | 92.70 |
M/O/CP-ATRA 3 mg/g | – | No | 70.56 | 99.23 | 97.29 | 94.55 | 92.75 |
M/O/CP-ATRA 5 mg/g | – | No | 73.59 | 99.02 | 96.85 | 95.20 | 92.11 |
M/O/CP-ATRA 7 mg/g | – | No | 69.28 | 99.05 | 96.28 | 94.98 | 92.83 |
M/O/CP-ATRA 9 mg/g | + | No | 69.85 | 98.88 | 96.01 | 94.25 | 92.47 |